Skip to main content

HIV PrEP

Featured Article

04/02/2025
Grace Taylor, MS, MA
A recent study shows rising pre-exposure prophylaxis (PrEP) utilization and declining costs as generic formulations replace branded versions in HIV prevention.
A recent study shows rising pre-exposure prophylaxis (PrEP) utilization and declining costs as generic formulations replace branded versions in HIV prevention.
A recent study shows rising...
04/02/2025
First Report Managed Care
News
07/24/2024
Grace Taylor, MS, MA
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise...
07/24/2024
First Report Managed Care
News
07/15/2023
Maria Asimopoulos
“Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle,” researchers advised.
“Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle,” researchers advised.
“Given overall acceptability,...
07/15/2023
First Report Managed Care
News
12/20/2022
Jolynn Tumolo
Researchers used clinic billing records in Washington, DC and Chicago to estimate the annual billable costs associated with the use of preexposure prophylaxis for HIV.
Researchers used clinic billing records in Washington, DC and Chicago to estimate the annual billable costs associated with the use of preexposure prophylaxis for HIV.
Researchers used clinic billing...
12/20/2022
First Report Managed Care
News
11/17/2022
Jolynn Tumolo
“Multiple participants suggested that initial counseling on PrEP should be offered universally to patients, regardless of sexual history or personal risk factors,” researchers advised.
“Multiple participants suggested that initial counseling on PrEP should be offered universally to patients, regardless of sexual history or personal risk factors,” researchers advised.
“Multiple participants suggested...
11/17/2022
First Report Managed Care
News
11/14/2022
Jolynn Tumolo
Investigators conducted a survey to determine how prevalent the use of pre- and post-exposure prophylaxis was among over 63,000 participants.
Investigators conducted a survey to determine how prevalent the use of pre- and post-exposure prophylaxis was among over 63,000 participants.
Investigators conducted a survey...
11/14/2022
First Report Managed Care
News
11/07/2022
Jolynn Tumolo
Among a variety of interventions, pre-exposure prophylaxis was the only method that showed consistent effectiveness in reducing the incidence of HIV, new findings show.
Among a variety of interventions, pre-exposure prophylaxis was the only method that showed consistent effectiveness in reducing the incidence of HIV, new findings show.
Among a variety of...
11/07/2022
First Report Managed Care
News
09/27/2022
Jolynn Tumolo
"Messages from health campaigns were perceived as most positive, and those from religious institutions as least positive," authors said.
"Messages from health campaigns were perceived as most positive, and those from religious institutions as least positive," authors said.
"Messages from health campaigns...
09/27/2022
First Report Managed Care
News
09/09/2022
Jolynn Tumolo
Study authors employed a strategy to monitor populations for HIV strains that are resistant to tenofovir and emtricitabine and ensure PrEP failure rates remain rare.
Study authors employed a strategy to monitor populations for HIV strains that are resistant to tenofovir and emtricitabine and ensure PrEP failure rates remain rare.
Study authors employed a...
09/09/2022
First Report Managed Care
News
09/02/2022
Jolynn Tumolo
High rates of psychological distress may represent an important barrier against HIV treatment adherence for Black men who have sex with men living in urban areas, researchers said.
High rates of psychological distress may represent an important barrier against HIV treatment adherence for Black men who have sex with men living in urban areas, researchers said.
High rates of psychological...
09/02/2022
First Report Managed Care
News
07/29/2022
Jolynn Tumolo
"While our findings showed some unanticipated relationships, they provide insight into how discrimination and stigma may influence PrEP use and disparities," researchers said.
"While our findings showed some unanticipated relationships, they provide insight into how discrimination and stigma may influence PrEP use and disparities," researchers said.
"While our findings showed some...
07/29/2022
First Report Managed Care

Newsfeed

News
07/24/2024
Grace Taylor, MS, MA
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise...
07/24/2024
First Report Managed Care
News
07/15/2023
Maria Asimopoulos
“Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle,” researchers advised.
“Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle,” researchers advised.
“Given overall acceptability,...
07/15/2023
First Report Managed Care
News
12/20/2022
Jolynn Tumolo
Researchers used clinic billing records in Washington, DC and Chicago to estimate the annual billable costs associated with the use of preexposure prophylaxis for HIV.
Researchers used clinic billing records in Washington, DC and Chicago to estimate the annual billable costs associated with the use of preexposure prophylaxis for HIV.
Researchers used clinic billing...
12/20/2022
First Report Managed Care
News
11/17/2022
Jolynn Tumolo
“Multiple participants suggested that initial counseling on PrEP should be offered universally to patients, regardless of sexual history or personal risk factors,” researchers advised.
“Multiple participants suggested that initial counseling on PrEP should be offered universally to patients, regardless of sexual history or personal risk factors,” researchers advised.
“Multiple participants suggested...
11/17/2022
First Report Managed Care
News
11/14/2022
Jolynn Tumolo
Investigators conducted a survey to determine how prevalent the use of pre- and post-exposure prophylaxis was among over 63,000 participants.
Investigators conducted a survey to determine how prevalent the use of pre- and post-exposure prophylaxis was among over 63,000 participants.
Investigators conducted a survey...
11/14/2022
First Report Managed Care
News
11/07/2022
Jolynn Tumolo
Among a variety of interventions, pre-exposure prophylaxis was the only method that showed consistent effectiveness in reducing the incidence of HIV, new findings show.
Among a variety of interventions, pre-exposure prophylaxis was the only method that showed consistent effectiveness in reducing the incidence of HIV, new findings show.
Among a variety of...
11/07/2022
First Report Managed Care
News
09/27/2022
Jolynn Tumolo
"Messages from health campaigns were perceived as most positive, and those from religious institutions as least positive," authors said.
"Messages from health campaigns were perceived as most positive, and those from religious institutions as least positive," authors said.
"Messages from health campaigns...
09/27/2022
First Report Managed Care
News
09/09/2022
Jolynn Tumolo
Study authors employed a strategy to monitor populations for HIV strains that are resistant to tenofovir and emtricitabine and ensure PrEP failure rates remain rare.
Study authors employed a strategy to monitor populations for HIV strains that are resistant to tenofovir and emtricitabine and ensure PrEP failure rates remain rare.
Study authors employed a...
09/09/2022
First Report Managed Care
News
09/02/2022
Jolynn Tumolo
High rates of psychological distress may represent an important barrier against HIV treatment adherence for Black men who have sex with men living in urban areas, researchers said.
High rates of psychological distress may represent an important barrier against HIV treatment adherence for Black men who have sex with men living in urban areas, researchers said.
High rates of psychological...
09/02/2022
First Report Managed Care
News
07/29/2022
Jolynn Tumolo
"While our findings showed some unanticipated relationships, they provide insight into how discrimination and stigma may influence PrEP use and disparities," researchers said.
"While our findings showed some unanticipated relationships, they provide insight into how discrimination and stigma may influence PrEP use and disparities," researchers said.
"While our findings showed some...
07/29/2022
First Report Managed Care
News
05/04/2026
Rebecca Amrick
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with...
05/04/2026
First Report Managed Care
News
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
04/27/2026
Rebecca Amrick
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study...
04/27/2026
First Report Managed Care
News
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care
Behind the Bill
04/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice...
04/23/2026
First Report Managed Care

Insights

Headshot of Brian Mustanski, Northwestern University
Interview
04/14/2022
Maria Asimopoulos
Brian Mustanski, PhD, professor of medical social sciences, Northwestern University, shares factors influencing whether patients reinitiate preexposure prophylaxis for HIV after discontinuation.
Brian Mustanski, PhD, professor of medical social sciences, Northwestern University, shares factors influencing whether patients reinitiate preexposure prophylaxis for HIV after discontinuation.
Brian Mustanski, PhD, professor...
04/14/2022
First Report Managed Care
Chris Beyrer
Podcasts
06/30/2021
Julie Gould
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Chris Beyrer, MD, infectious disease epidemiologist and professor at Johns Hopkins Bloomberg School of Public Health, breaks down current rates of HIV across the United States as well as the challenges linked with controlling this...
Chris Beyrer, MD, infectious...
06/30/2021
First Report Managed Care
Podcasts
01/25/2021
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to...
Ed Pezalla, MD, CEO,...
01/25/2021
First Report Managed Care
Videos
09/23/2020
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class...
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class...
Max Lataillade, DO, head of...
09/23/2020
First Report Managed Care